Karolinska Development AB Company Modus To Present Poster At 58th American Society of Hematology Annual Meeting In San Diego

STOCKHOLM - December 1, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) notes the announcement today from its portfolio company Modus Therapeutics AB, a clinical-stage drug development company focused on innovative treatments for patients with sickle cell disease (SCD), will present a poster at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego on 4th December. The ASH Annual Meeting is a world-leading event in malignant and non-malignant hematology.

Details from the Modus Therapeutics press release follow:

The poster entitled: Sevuparin Blocks Sickle Blood Cell Adhesion and Sickle-Leukocyte Rolling on Immobilized L-Selectin in a Dose Dependent Manner covers a study, focusing on microfluidic flow-based functional blood analysis, conducted by Modus Therapeutics in a research collaboration with Functional Fluidics LLC of Detroit in the U.S.

In patients with SCD it has been shown that the cause and continuation of vaso-occlusion are fueled by the sickle red blood cells’ interactions with multiple other cell populations, promoting inflammation, obstructing the vasculature, and injuring the endothelium, leading to broad manifestations that affect most vital organs.

The data presented at ASH showed that sevuparin acts in a multicellular manner, blocking both firm adhesion by sickle red blood cells and L-selectin-mediated rolling adhesion of sickle-leukocytes, as well as functionally by interacting with another key adhesion receptor VCAM-1.

These results provide further insights into sevuparin’s multimodal action and its potential clinical benefits in treating the complex mechanisms manifested in vaso-occlusion and complications in SCD.

The poster will be presented on Sunday, December 4, 2016 6:00 pm - 8:00 pm PDT in Hall GH at the San Diego Convention Center.

Sevuparin is currently being evaluated in a clinical PII study in acute vaso-occlusive crisis in hospitalized SCD patients ( NCT02515838). In addition, Modus Therapeutics is planning to conduct a further clinical study to evaluate sevuparin for early treatment of symptoms of vaso-occlusion in an at-home setting.

Back to news